Jane B., a woman in her early forties, developed extreme anxiety, night sweats, insomnia, and unusual sensations that she described as electric shocks. Her physician initially dismissed perimenopause as unlikely given her age and instead increased her antidepressant dosage. After consulting a menopause specialist and beginning hormone therapy, her symptoms improved dramatically.

The author reflects on her own mother’s experience during perimenopause in her forties, when she relied on Butisol, a barbiturate prescribed to help her manage overwhelming stress from running a restaurant, raising eight children, and coping with family grief and challenges. Only later did the author learn that her mother’s mental health had been suppressed with a depressant of the central nervous system rather than addressed through any discussion of hormones.

Research now confirms that mood-related symptoms emerging during perimenopause often have biological rather than purely psychological origins. The hormonal fluctuations mirror those seen in postpartum depression and premenstrual dysphoric disorder, both recognized as hormonally driven conditions. Research indicates that up to 50% of women may experience heightened depressive symptoms during perimenopause, and a significant number of women report mood swings, anxiety, depression, or panic attacks. These hormonal shifts create a unique depression and anxiety profile, yet no formal diagnostic category for perimenopause-related mood disorders exists in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

Irritability, present in roughly 40% of perimenopausal women, represents a clinically distinct mood state that bridges anxiety and depression. However, this symptom is frequently dismissed or self-blamed. Women presenting with mood symptoms to their physicians are often under-evaluated for hormonal factors, even when they simultaneously report hot flashes or genitourinary issues. This oversight leads to the widespread prescription of antidepressants that may not address the underlying hormonal instability. Emerging evidence suggests that hormone therapy, particularly transdermal estradiol, may be more effective and safer than selective serotonin reuptake inhibitors (SSRIs) for treating new-onset mood disorders that clearly align with hormonal disruption.

Despite mounting scientific support, medical practice remains slow to embrace hormone therapy for mental-health applications. An integrated approach combining hormone therapy when appropriate, targeted pharmacological treatments, and lifestyle modifications offers the most effective care. Women experiencing mental-health changes should prioritize self-advocacy, consider therapy for unaddressed trauma, and implement evidence-based lifestyle strategies including regular exercise, specific diets, improved sleep hygiene, stress management practices, and maintaining strong social connections.

Amanda N., an OB-GYN sonographer, developed brain fog and attention difficulties during perimenopause that made her fear early-onset dementia. She also experienced leg and hip pain, heart palpitations, itchy ears, and constant eye watering.

Patients commonly report struggling at work or experiencing embarrassing cognitive lapses. Others describe symptoms resembling attention-deficit/hyperactivity disorder (ADHD), including chronic disorganization, time-management difficulties, and feelings of inadequacy. Roughly 85% of perimenopausal women report some degree of cognitive disruption like brain fog, a collection of symptoms including memory lapses, concentration issues, slowed thinking, and mental fatigue. Research documents small but consistent declines in memory performance and executive function during the menopausal transition.

Estrogen functions as what researchers call a “master regulator” of brain function. Brain regions crucial for memory, focus, and emotional regulation contain dense concentrations of estrogen receptors, making them particularly vulnerable to hormonal fluctuations. As estrogen levels decline, the brain compensates by building additional estrogen receptors, a process associated with increased neurological symptoms. This work importantly distinguishes the effects of hormonal aging from chronological aging.

Haver notes that the workplace impact of cognitive changes during perimenopause is significant but under-recognized. Women seeking medical care for menopause-related symptoms can experience a 10% reduction in earnings due to reduced work hours or leaving employment entirely. Menopause symptoms can result in an estimated $1.8 billion in annual lost work time in the United States, rising to $26.6 billion when medical expenses are included.

For most women, cognitive changes during perimenopause prove temporary, with mental clarity returning in the more stable low-estrogen environment of post-menopause. However, women with a first-degree relative with Alzheimer’s disease or who carry genetic indicators for the disease face elevated risk . Nearly two-thirds of all Alzheimer’s cases occur in women, possibly linked to the hormonal shifts of menopause. Concerning signs beyond typical brain fog include withdrawal from social relationships and difficulty managing everyday tasks.

The Everyday Memory Questionnaire (Revised) became the first validated tool for measuring memory and attention difficulties in menopausal women, marking an important shift from tools designed solely to detect dementia. Hormone therapy has emerged as a potential intervention for cognitive symptoms, showing improved effectiveness when initiated early in perimenopause. Current medical guidelines do not recommend hormone therapy solely for cognitive function, but the author argues that these guidelines rely on outdated studies that do not reflect modern clinical practice.

The overlap between perimenopause and adult ADHD presents diagnostic challenges. Diagnoses of ADHD in women aged 30 to 49 nearly doubled between 2020 and 2022. This could be due to pre-existing ADHD that worsens alongside declining estrogen; undiagnosed perimenopause causing hormone-driven cognitive dysfunction; or true ADHD that has been misdiagnosed as depression, anxiety, or normal aging. ADHD medications, as well as hormone therapy, can improve cognitive function in midlife women regardless of formal ADHD diagnosis. An integrated approach combining appropriate medication, lifestyle interventions, and careful hormonal assessment offers the most effective care. Haver encourages lifestyle habits supporting brain health and engaging in cognitively stimulating activities that maintain neuroplasticity.

Stephanie S., a vascular surgeon and single mother in her early fifties, developed severe exhaustion, night waking, night sweats, anxiety with palpitations, brain fog, and unexplained weight gain over an eight-month period, initially attributing her symptoms to stress. Laboratory testing revealed elevated cholesterol and cortisol consistent with perimenopause. After beginning hormone therapy, she experienced significant improvement.

The author recounts her personal experience of discovering unexpectedly elevated LDL cholesterol and rising blood pressure in her late forties despite maintaining consistent healthy lifestyle habits. She observed similar patterns among her patients, whose treatment rarely involved any discussion of underlying hormonal causes.

Metabolic syndrome comprises a cluster of conditions that dramatically increase the risk of cardiovascular disease, type 2 diabetes, and certain cancers. Being postmenopausal is recognized as an independent risk factor. Recent research confirms that menopause itself, regardless of age, represents a major driver of metabolic shifts that can develop in otherwise healthy women with unchanged lifestyle habits.

The author and a research team have introduced the concept of the metabolic syndrome of menopause, presented at the Endocrine Society meeting in July 2024 and currently under review for publication. This framework recognizes the metabolic changes driven by estrogen decline, including preferential abdominal weight gain, rising insulin resistance, altered cholesterol profiles, muscle loss, and fatty liver disease.

Estrogen’s metabolic protection operates in tissues including fat, muscle, the liver, and the pancreas. Dropping estrogen levels leads to larger fat cells, increased inflammation, insulin resistance, and muscle loss. Before menopause, estrogen directs fat storage to hips and thighs as relatively harmless subcutaneous fat. During perimenopause, fat accumulation shifts to the abdomen, all without dietary or activity changes, and leads to several potential health issues. Fading estrogen protection also increases chronic low-grade inflammation, contributing to age-related diseases.

There are tests for women to help indicate rising fat accumulation or inflammation, and menopause hormone therapy (MHT) can help redistribute fat to peripheral areas, though this benefit diminishes after stopping treatment. Additionally, medications like GLP-1 receptor agonists represent an emerging evidence-based therapy and can improve insulin sensitivity, reduce appetite, promote weight loss, and lower inflammation. Research suggests that they may work synergistically with estrogen, offering particular benefits for addressing cardiovascular and metabolic risks that rise sharply during perimenopause.

Haver describes numerous significant health complications as a result of fading estrogen and other perimenopausal and menopausal symptoms. Insulin resistance develops as estrogen’s protective effects on glucose metabolism fade. Without adequate estrogen, chronic inflammation causes blood sugar to remain elevated. Haver emphasizes that signs of insulin resistance can begin early and recommends tests to check for them.

High blood pressure affects more women than men after age 60, primarily due to estrogen loss. Estrogen maintains vascular health, while declining estrogen can cause a rise in blood pressure. Women experiencing surgical menopause face even more dramatic increases. Haver highlights transdermal estrogen formulations, which prove safer than oral versions. She also recommends tests—such as a lipid panel—for cholesterol levels.

Finally, certain liver diseases occur at significantly higher rates in postmenopausal women, particularly those who have not received hormone therapy. Estrogen deficiency, combined with insulin resistance and altered lipid metabolism, promotes fat accumulation in the liver. Women experiencing early menopause, naturally or surgically, face a 90% increased risk of severe liver fibrosis. Standard liver-function tests included in comprehensive metabolic panels can detect early changes.

Annual monitoring during perimenopause should include HOMA-IR assessment, body-composition measurement, inflammatory markers, blood-pressure testing, and comprehensive lipid panels. Strategic prevention and treatment combine regular resistance training and cardiovascular exercise with anti-inflammatory, nutrient-dense nutrition emphasizing fiber, healthy fats, lean proteins, and phytoestrogens. When lifestyle interventions prove insufficient, MHT can function as metabolic therapy, improving lipid profiles, enhancing insulin sensitivity, and reducing inflammation. For women with more significant metabolic challenges, GLP-1 medications combined with lifestyle modifications may reduce insulin resistance, lower inflammation, and produce substantial weight loss.

Formal recognition of the metabolic syndrome of menopause would shift medical practice from a reactive treatment model to proactive prevention, enabling care that accounts for the full complexity of women’s hormonal and metabolic environments during this critical transition.

Marcie D. began experiencing various symptoms after returning to work at age 40. These issues were attributed to extraneous factors. An unexpected osteoporosis diagnosis at age 52 prompted her to investigate perimenopause more thoroughly and eventually begin hormone therapy, which she wishes had been recommended earlier.

Osteoporosis progressively weakens bones, making them thin and brittle, yet it typically produces no early warning symptoms. The disease often reveals itself only through fracture, which may occur much earlier than most women expect. Accelerated bone loss begins during perimenopause, years before standard screening guidelines recommend testing. Women face a 40% to 51% lifetime risk of sustaining an osteoporotic fracture after age 50.

Citing her own mother’s troubles with bone density, the author notes how only 26.5% of eligible women in the US actually receive the recommended testing after 65 for bone density. These guidelines fail to account for the rapid bone loss occurring during the menopause transition, often leaving women undiagnosed until after their first fracture.

Estrogen plays a crucial regulatory role in maintaining bone density. As estrogen levels fluctuate and decline during perimenopause, bone breakdown accelerates beyond its ability to rebuild, creating net bone loss particularly in perimenopause. Other hormones also influence bone health during this transition. Progesterone works with estrogen in bone formation, with elevated levels during ovulation providing bone-building effects that may diminish as ovulation becomes irregular.

Women typically reach peak bone-mineral density in their mid-twenties, after which bone becomes something to maintain rather than build. In early perimenopause, bone density in the lumbar spine and femoral neck declines by roughly 0.14% and 0.11% annually, respectively. These rates potentially reach 6.3% per year in late perimenopause. By menopause, women may have lost 10% to 20% of total bone mass. This degradation of internal bone architecture threatens the structural stability essential for mobility and independence. Chronic back pain affects a large percentage of postmenopausal women with osteoporosis and often results from undiagnosed vertebral fractures.

This pain should not be dismissed as normal aging. The author advocates for baseline DEXA scans for women in their late forties or early fifties, particularly those with risk factors. Early detection provides powerful motivation for intervention. Screening protocols should also account for variations based on race and body composition. The FRAX tool calculates 10-year fracture probability based on clinical factors and bone-mineral density, helping guide treatment decisions. However, it was designed for postmenopausal populations and may underestimate risk in younger midlife women experiencing rapid hormonal shifts.

Treatment strategies should combine multiple approaches. Estrogen therapy represents the most direct hormonal intervention, reducing fracture risk by suppressing bone breakdown. Large-scale trials show that hormone therapy reduces vertebral fractures by up to 34% and hip fractures by 27% when initiated within 10 years of menopause. Haver again recommends transdermal estradiol. For women with persistent low bone density despite estrogen or symptoms of androgen deficiency, testosterone may provide additional benefits.

Non-hormonal pharmacologic options include bisphosphonates; denosumab, particularly useful for women with kidney impairment; selective estrogen receptor modulators like raloxifene; calcitonin for painful vertebral fractures; and anabolic agents reserved for severe osteoporosis. Romosozumab shows promise as a dual-action medication but requires cardiovascular risk assessment.

The author notes how research shows that women performing jump training while wearing weighted vests maintained hip-bone density and significantly reduced their fracture risk. Additionally, lifestyle interventions provide the foundation for long-term bone health, such as weight-bearing and resistance exercises. The LIFTMOR trial demonstrated significant improvements in bone density through high-intensity resistance and impact training. Maintaining calcium and vitamin D intake is also important. Adequate protein intake supports both muscle mass and collagen synthesis within bone, and avoiding smoking, moderating alcohol consumption, and prioritizing restorative sleep further support bone health.

Haver closes the chapter by asserting that skeletal security must be addressed during the finite window of perimenopause through early screening, targeted prevention, and prompt intervention rather than waiting for inevitable decline.

Wendy C. discovered that she was perimenopausal at age 37 but felt like the concerns about protecting heart, bones, and brain did not apply to someone her age. She ignored numerous symptoms for years until an osteoporosis diagnosis at 53 finally prompted her to begin hormone therapy. She regrets not taking action earlier, believing her health trajectory would have been different.

Sarcopenia, the progressive loss of muscle mass, strength, and function, begins during perimenopause rather than in old age as commonly believed. Initial signs may be subtle—clothes fitting differently, grocery bags feeling heavier, extended soreness after workouts—before women recognize that they feel genuinely weaker. This loss reflects how declining estrogen levels degrade skeletal muscle similarly to how they erode bone density. Under normal hormonal conditions, estradiol (an estrogen steroid hormone) supports muscle repair and adaptation following exercise or injury. Falling estradiol levels during perimenopause impair regenerative capacity. The body loses both muscle mass and the ability to rebuild it effectively.

Estrogen also maintains mitochondrial function within muscle cells, supporting the generation of energy-carrying molecules called ATP. Declining estrogen leads to decreased energy availability, increased fatigue, and slower recovery after exercise. Additionally, systemic inflammation rises, muscle breakdown accelerates, and insulin sensitivity declines.

Research documents 15% to 20% reductions in muscle mass and strength following ovarian function loss. The Study of Women’s Health Across the Nation found that women lose an average of 1% to 2% of lean body mass annually during the menopausal transition, primarily from areas critical for mobility, stability, and fracture prevention. Hormone therapy initiated during early post-menopause has been shown to preserve lean mass and improve muscle quality, particularly when combined with resistance training. However, evidence suggests that this benefit provides roughly a three-year window before age-related decline resumes, emphasizing that hormonal signaling and mechanical loading (such as physical training and weight resistance) work synergistically.

Muscle loss triggers a metabolic domino effect impacting multiple aspects of health. Skeletal muscle critically maintains insulin sensitivity and regulates blood sugar. Declining lean mass opens pathways to insulin resistance, unexpected weight gain, central adiposity, and prediabetes. Loss of muscle mass is strongly associated with increased visceral fat, contributing to systemic inflammation, abnormal lipid levels, and elevated cardiovascular risk. Skeletal muscle also supports a healthy metabolism, immune function, and cognitive resilience. As muscle mass and activity decline, production of these protective compounds diminishes, creating a more pro-inflammatory, insulin-resistant environment that accelerates aging across multiple systems.

Dr. Gabrielle Lyon has termed muscle the “organ of longevity,” and Dr. Wright introduced the concept of the “musculoskeletal syndrome of menopause” (147), which can be proactively treated through earlier screening, prescribed resistance training, supported protein intake, and discussions about muscle and bone health before loss occurs. Dr. Abbie Smith-Ryan’s research in exercise physiology has illuminated how resistance training combined with targeted nutrition strategies, particularly protein distribution and creatine supplementation, helps women preserve lean mass and metabolic function throughout the menopause transition.

Building and preserving muscle requires layered strategies combining movement, nutrition, and—when appropriate—hormonal support. Resistance training represents the most effective intervention. Studies show that twice-weekly progressive resistance training can produce two- to four-pound gains in lean mass over 12 to 24 weeks in postmenopausal women. Focus should emphasize consistency and functional movements like squats, lunges, rows, and loaded carries that translate to improved real-world strength and reduced fall risk.

Nutritional interventions prove essential for muscle maintenance. Most midlife women consume insufficient protein and distribute it poorly across meals. Evidence supports a target of 1.2 to 1.6 grams per kilogram of body weight daily, with approximately 25 to 30 grams per meal to maximally stimulate muscle development. In addition, three to five grams daily of creatine monohydrate enhances lean mass gains and muscular power when paired with resistance training. It may also support cognitive performance and bone density. Vitamin D and magnesium should be optimized for muscle function and recovery.

MHT serves as a valuable complement to training and nutrition rather than a substitute. While a 2024 review found no consistent evidence that hormone therapy alone improves muscle strength or mass, transdermal estradiol appears effective when combined with resistance training, amplifying anabolic responses and improving muscular adaptation in early menopause. Carefully monitored testosterone also warrants consideration for women with low levels experiencing fatigue, low libido, or persistent muscle loss despite intervention.

Muscle represents a highly responsive tissue where midlife intervention can build strength, improve body composition, and shift metabolic trajectory. The critical imperative is early action during perimenopause when preservation remains achievable, rather than waiting until muscle loss reaches clinical sarcopenia and independence is already compromised.

Caroline H. entered perimenopause at age 38 but went undiagnosed as her doctors attributed her symptoms to other causes. She was informed that her symptoms were due to relationship issues, inadequate exercise, and her diet. She felt gaslit through one of the most challenging transitions of her life by physicians who should have recognized her symptoms.

The author shares her personal experience with perimenopausal sleep disruption. Even after hormone therapy resolved her hot flashes, the awakenings continued. Once disturbed, sleep architecture often requires consistent, intentional effort to rebuild. She now maintains strict sleep hygiene and notes that alcohol consumption virtually guarantees nighttime waking.

Research shows that the perimenopausal brain becomes more sensitive to disruption. Unreliable ovulation reduces progesterone, which has pronounced calming effects on the nervous system. Declining estrogen diminishes melatonin production and causes cortisol spikes that fall out of sync with circadian rhythms. Without reliable hormonal buffering, factors like stress, sugar, alcohol, or screen time can severely destabilize sleep. Sleep medicine physician Dr. Andrea H. Matsumura has noted that women often attribute poor sleep to life circumstances like childcare, eldercare, or perimenopausal symptoms.

Epidemiological studies indicate that approximately 40% to 50% of perimenopausal women report significant sleep disturbances. Sleep disruptions carry long-term physical and mental-health risks, with daytime fatigue, anxiety, and cognitive complaints as common consequences. These disturbances can manifest as difficulty falling asleep, multiple nighttime awakenings, or middle-of-the-night waking with inability to return to sleep, as well as hot flashes and night sweats. Beyond these, other contributors include restless legs syndrome, obstructive sleep apnea, frequent nighttime urination, and the paradoxical state of feeling physically exhausted yet mentally alert.

Obstructive sleep apnea risk increases in menopause, yet an estimated nine out of 10 women with the condition remain undiagnosed. Women often present with atypical symptoms including persistent fatigue, insomnia, morning headaches, anxiety, depression, concentration difficulties, frequent nighttime urination, and episodes of waking with racing heart or shortness of breath. These symptoms are frequently misattributed, leading to delayed treatment. A simple home sleep study can provide a diagnosis for this treatable condition.

Estrogen plays a central role in sleep regulation, while progesterone functions as the body’s natural sedative. During regular ovulatory cycles, rising progesterone in the luteal phase promotes deeper sleep, but when ovulation becomes sporadic during perimenopause, this hormonal drop causes the nervous system to become more reactive.

Sleep architecture also changes in perimenopause. Reduced slow-wave and REM sleep and shifting melatonin levels can make the entire hormonal ecosystem supporting circadian rhythm less reliable. Women may spend eight hours in bed yet wake exhausted because their sleep is lighter and less restorative. Mood disturbances and vasomotor symptoms can amplify the problem, with anxiety, depression, or trauma history increasing vulnerability to disrupted sleep.

Cortisol represents an under-recognized sleep disruptor during perimenopause. Cortisol normally follows a circadian rhythm, with highest levels in early morning to support waking and tapering throughout the day. In perimenopause, this rhythm can dysregulate, causing middle-of-the-night cortisol spikes that disrupt sleep. Chronic nighttime cortisol spikes link to insulin resistance, abdominal fat accumulation, poor memory consolidation, and heightened risk for anxiety and depression.

Evidence-based treatment strategies address the biological roots of sleep disruption. MHT directly counteracts hormonal fluctuations. Estrogen therapy reduces nighttime awakenings, while micronized progesterone improves both sleep onset and maintenance. Clinical trials have shown that this combination is particularly effective for women reporting insomnia as a primary perimenopausal symptom. Additionally, cognitive behavioral therapy for insomnia (CBT-I) uses structured techniques to retrain the brain’s relationship with sleep. Studies demonstrate that CBT-I proves as effective or more effective than pharmacological sleep aids with longer-lasting results. Digital and telehealth-based programs make this intervention increasingly accessible.

Lifestyle interventions require nuanced attention during perimenopause. A high-protein, anti-inflammatory diet helps stabilize blood sugar and cortisol levels, while regular strength training improves sleep quality alongside muscle and metabolic health. Creating a wind-down period with dimmed lights, reduced screen time, and consistent bedtime reinforces circadian rhythms. Many women develop new intolerance to alcohol, with evening consumption leading to rebound cortisol surges, shallow sleep, and early-morning awakenings.

Targeted supplements and medications provide additional support. Prescription options include low-dose doxepin, gabapentin, and certain SSRIs or serotonin-norepinephrine reuptake inhibitors (SNRIs) supporting sleep in women experiencing mood disturbances or severe night sweats. Nutritional supplements showing promise include magnesium and melatonin. Combination supplements blending these ingredients have demonstrated effectiveness in clinical trials.

Daily stress-management practices prove essential rather than optional in perimenopause. Even brief, consistent practices like mindfulness meditation, breathing exercises, or yoga can help. Additional strategic considerations include ruling out sleep disorders, obtaining sleep studies, checking iron and vitamin D levels, and addressing trauma or unresolved anxiety through therapy.

Haver states that better sleep in perimenopause is achievable through education, appropriate tools, and recognition that sleep disruption represents a biological phenomenon worthy of serious medical attention rather than another casualty of midlife to be endured.